The settlement involves Glenmark Pharmaceuticals Inc., USA and a group of state attorneys general in the US. The amount will be paid in annual instalments over five years, the company said in an exchange filing on May 23.
The litigation relates to allegations of price-fixing, market allocation and anti-competitive conduct in the generic pharmaceutical market. Since 2016, Glenmark USA has been named in more than 35 complaints filed by direct purchasers, end-payers, indirect purchasers and multiple US states.
The company said Glenmark USA has denied all allegations and that the settlement “does not constitute any concession or admission of liability, wrongdoing, or illegality”.
Glenmark added that the full settlement amount has already been provided for in its financial statements and the payout will not have a significant impact on the company’s financial position.
First Published: May 23, 2026 1:56 PM IST
